Dipexium Pharmaceuticals, Inc. is a late-stage pharmaceutical company. The Company is focused on the development and commercialization of Locilex, a topical antibiotic. Locilex is a chemically synthesized, 22-amino acid peptide isolated from the skin of the African Clawed Frog. Its mechanism of action kills microbial targets by disrupting the bacterial cell membrane. Locilex is focused on the treatment of mild infections of diabetic foot ulcers (Mild DFI). Locilex affects only the area to which it is applied. Locilex has demonstrated statistical non-inferiority to a systemic antibiotic in a clinical study in patients with Mild or Moderate DFI. It has conducted microbiology studies that highlight the sensitivity of resistant bacteria, including methicillin-resistant staphylococcour aureour (MRSA), vancomycin-resistant enterococcour (VRE), extended-spectrum b-lactamase (ESBL) and multi-drug resistant (or MDR) bacteria, to pexiganan, the active pharmaceutical ingredient (API) in Locilex.